Protocols

Adaptimmune raises $106M for pipeline work; KaloBios chief says biotech is on track for Chagas drug filing

Cameron Durrant

→ Matrix Capital Management has scooped up $42 million worth of Adaptimmune stock $ADAP, paying a slight premium for the block of shares. “We are delighted to welcome Matrix to our shareholder base through a purchase of 7 million ADSs, which raises a further $42 million to add to the $62 million raised in our public offering, which closed last week,” says CEO James Noble.

→ Australia’s Novogen $NVGN is dropping a preclinical therapy after concluding that it didn’t have much of a future. It’s now cutting its headcount by an unspecified number and focusing on its clinical efforts.

→ KaloBios CEO Cameron Durrant says the company is still on track with its development plans for benznidazole for Chagas disease. The biotech $KBIO plans to file its IND in May and, with the FDA’s approval, use existing data to help with an NDA filing in early 2018.


Get Endpoints News in your inbox

News reports for those who discover, develop, and market drugs. Join 16,000+ biopharma pros who read Endpoints News articles by email every day. Free subscription.

Quick Subscribe

You're subscribing to Endpoints News

John Carroll, Editor and Co-Founder

We produce two daily newsletters designed to give you a complete picture of what's important in biopharma.

Early Edition is a skimmable digest of original sources you need to see by ~7:15a ET, and our Main Edition is the daily chronicle of biotech, with every story inside the email ~11:55a ET.
2x/weekdays. Privacy policy